TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16448475

Group type: EXPERIMENTAL
Intervention: LGG-supplemented formula
Number of subjects: 120

Group type: COMPARATOR
Intervention: Regular formula
Number of subjects: 120
Study: 12760625

Group type: EXPERIMENTAL
Intervention: Observation of action performed by a human actor with a distractor present
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observation of action performed by a human actor without a distractor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catch trials where the actor was seated but no action was demonstrated
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring gaze direction of the actor
Number of subjects: 0
Study: 11327415

Group type: EXPERIMENTAL
Intervention: Norian SRS (self-setting hydroxyapatite) with wrist immobilization for 2 weeks (n=12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: External fixation with immobilization for 5 weeks (n=11)
Number of subjects: 23
Study: 9863113

Group type: EXPERIMENTAL
Intervention: Q-wave millimeter microwave (QWMM) irradiation starting 10 days after operation and combined with chemotherapy on the 16th day (Group A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Q-wave millimeter microwave (QWMM) irradiation starting immediately after chemotherapy induced peripheral WBC reduction (Group B)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combined effective rate of both groups
Number of subjects: 62
Study: 8347733

Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg body wt. daily s.c. GM-CSF
Number of subjects: 44

Group type: COMPARATOR
Intervention: 5 micrograms/kg body wt. daily s.c. GM-CSF
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both dosages of GM-CSF
Number of subjects: 44
Study: 2939636

Group type: EXPERIMENTAL
Intervention: prednicarbate 0.25% in emulsifiable greasy ointment without water
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: prednicarbate 0.25% in w/o emulsion (ointment)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: prednicarbate 0.25% in o/w emulsion (cream)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: prednicarbate 0.25% in various vehicles
Number of subjects: 383
Study: 31981587

Group type: EXPERIMENTAL
Intervention: Sugar content signage
Number of subjects: 3034

Group type: EXPERIMENTAL
Intervention: Health Star Rating signage
Number of subjects: 3034

Group type: EXPERIMENTAL
Intervention: Graphic health warning signage
Number of subjects: 3034

Group type: COMPARATOR
Intervention: No signage (control)
Number of subjects: 3034
Study: 28749734

Group type: EXPERIMENTAL
Intervention: Bitter orange (500 mg capsules)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Lavender (500 mg capsules)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control (starch, 500 mg capsules)
Number of subjects: 156
Study: 28606422

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking), 3 times per week for 24 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 39
Study: 25233298

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 135

Group type: COMPARATOR
Intervention: Fever control
Number of subjects: 135
Study: 23283539

Group type: EXPERIMENTAL
Intervention: Ultrasound treatment and exercises
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phonophoresis and exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exercises only (Control)
Number of subjects: 60
Study: 20054280

Group type: EXPERIMENTAL
Intervention: Corrected C/G ratio
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Normal responses
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Augmented responses
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Raw and corrected amplitudes of c-VEMP
Number of subjects: 21
Study: 18202563

Group type: EXPERIMENTAL
Intervention: Active recovery (submaximal cycling at 60% of HRpeak and low‐intensity resistance training at < 50% 1RM)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 17
Study: 16827385

Group type: EXPERIMENTAL
Intervention: Autologous osteochondral transplantation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cleaning and drilling procedures
Number of subjects: 25
Study: 15257735

Group type: EXPERIMENTAL
Intervention: Access flap surgery followed by root surface and defect debridement using an Er:YAG laser (KEY3) (160 mJ, 10 Hz)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Access flap surgery followed by root surface and defect debridement using hand and ultrasonic instruments
Number of subjects: 23
Study: 10905076

Group type: EXPERIMENTAL
Intervention: Ureaplasma urealyticum vaginosis
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 166
Study: 9224864

Group type: EXPERIMENTAL
Intervention: MENTAL
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LOUD
Number of subjects: 8

Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 8
Study: 8467888

Group type: EXPERIMENTAL
Intervention: Increased speed of movement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viscous resistive load
Number of subjects: 0
Study: 3950448

Group type: EXPERIMENTAL
Intervention: Presence of spiral bacteria in specimens with gastritis (n=39)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Presence of spiral bacteria in normal specimens (n=7)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Presence of spiral bacteria in gastric ulcer patients (n=17)
Number of subjects: 50
Study: 31937322

Group type: EXPERIMENTAL
Intervention: Simultaneous reduction of flow and FiO2
Number of subjects: 100

Group type: COMPARATOR
Intervention: Flow reduction (FR) first
Number of subjects: 100

Group type: COMPARATOR
Intervention: FiO2 reduction (OR) first
Number of subjects: 100
Study: 29947695

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) with two pressure levels, once a day for 60 min from the 1st to the 3rd postoperative day (POD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group received guidelines regarding posture, early ambulation, and cough stimuli
Number of subjects: 50
Study: 26748736

Group type: EXPERIMENTAL
Intervention: Concise Health Risk Tracking Self‐Report (CHRT)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Columbia Suicide Severity Rating Scale (CSSRS)
Number of subjects: 482
Study: 24733770

Group type: EXPERIMENTAL
Intervention: Pharmacist case management (active prescribing)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Nurse-led case management (screening and feedback)
Number of subjects: 279
Study: 22197301

Group type: EXPERIMENTAL
Intervention: Face-to-face personalized feedback intervention (PFI) with a live interviewer
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Computer-delivered personalized feedback intervention (PFI) with a video interviewer
Number of subjects: 152

Group type: COMPARATOR
Intervention: Comprehensive assessment condition
Number of subjects: 152

Group type: COMPARATOR
Intervention: Minimal assessment-only condition
Number of subjects: 152
Study: 20064578

Group type: EXPERIMENTAL
Intervention: Nap in a seat (NS)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nap in a bed (NB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No-nap (NN)
Number of subjects: 36
Study: 18312805

Group type: EXPERIMENTAL
Intervention: Tailored telephone intervention
Number of subjects: 598

Group type: COMPARATOR
Intervention: Standard print intervention
Number of subjects: 598
Study: 11574357

Group type: EXPERIMENTAL
Intervention: Nasal Cannula (NC) 2-4 L/min
Number of subjects: 190

Group type: COMPARATOR
Intervention: Room Air
Number of subjects: 190
Study: 9745969

Group type: EXPERIMENTAL
Intervention: Ephedrine hydrochloride tablets after lunch and before bedtime for 2 months
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group treatments (imipramine hydrochloride, desmoporessin, ritaline, cetiprin, or behavioral therapy)
Number of subjects: 300
Study: 8186113

Group type: EXPERIMENTAL
Intervention: Copper vapour laser (CVL) at 578 nm, mean fluence 18.2 J/cm2, mean pulse width 50 ms
Number of subjects: 43

Group type: COMPARATOR
Intervention: Pulsed tunable dye laser (PTDL) at 585 nm, 6.5 J/cm2
Number of subjects: 43
Study: 3373404

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1 mg/kg)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Indomethacin (low-weight subgroup)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Indomethacin (high-weight subgroup)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo (high-weight subgroup)
Number of subjects: 122
Study: 30600137

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (QW) 2 mg
Number of subjects: 295
Study: 28160326

Group type: EXPERIMENTAL
Intervention: Conjunctival provocation test with peanut extract
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Oral peanut provocation (double-blind placebo-controlled)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (peanut-tolerant children)
Number of subjects: 102
Study: 25535318

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) workshop plus behavioral family intervention (BFI)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 59
Study: 23235135

Group type: EXPERIMENTAL
Intervention: Early surfactant administration (n = 74)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Late surfactant administration (n = 79)
Number of subjects: 153
Study: 21645196

Group type: EXPERIMENTAL
Intervention: Monovalent, adjuvanted vaccine against influenza A/H1N1 (n=16)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham procedure (control group, n=8)
Number of subjects: 24
Study: 18981932

Group type: EXPERIMENTAL
Intervention: Child CBT
Number of subjects: 128

Group type: COMPARATOR
Intervention: Family CBT
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Younger children
Number of subjects: 128
Study: 16781986

Group type: EXPERIMENTAL
Intervention: Home administration of intravenous methylprednisolone
Number of subjects: 138

Group type: COMPARATOR
Intervention: Outpatient administration of intravenous methylprednisolone
Number of subjects: 138
Study: 12612196

Group type: EXPERIMENTAL
Intervention: Pulse transit time (PTT) measurement
Number of subjects: 34

Group type: COMPARATOR
Intervention: EEG arousal measurement
Number of subjects: 34
Study: 10720861

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% plus epinephrine (5 microg/ml)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 69
Study: 9196086

Group type: EXPERIMENTAL
Intervention: Zafirlukast (80 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of zafirlukast and loratadine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study: 1347280

Group type: EXPERIMENTAL
Intervention: Olsalazine 500 mg bd
Number of subjects: 227

Group type: COMPARATOR
Intervention: Sulphasalazine 1 g bd
Number of subjects: 227
Study: 31849027

Group type: EXPERIMENTAL
Intervention: Buprenorphine (4 or 6 mg/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 29767739

Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Number of subjects: 2519

Group type: COMPARATOR
Intervention: qHPV vaccine
Number of subjects: 2519
Study: 26555602

Group type: EXPERIMENTAL
Intervention: Algisyl with standard medical therapy (SMT)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT) alone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Algisyl with SMT
Number of subjects: 78
Study: 23822617

Group type: EXPERIMENTAL
Intervention: Manual-based programme combining CBT with job skills training
Number of subjects: 109

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 109
Study: 22480818

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/d
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/d (after week 4 for non-responders)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 20873934

Group type: EXPERIMENTAL
Intervention: Negations in descriptions of stereotype-inconsistent behavior
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negations in descriptions of behavior
Number of subjects: 0
Study: 18785413

Group type: EXPERIMENTAL
Intervention: Autologous fat granules with microskin in mixed grafting (volume ratio 1:1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Autologous microskin grafting only
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Autologous fat granules with microskin in mixed grafting
Number of subjects: 20
Study: 16823364

Group type: EXPERIMENTAL
Intervention: Usual insulin dose
Number of subjects: 16

Group type: COMPARATOR
Intervention: Reduced insulin dose (1/3 reduction)
Number of subjects: 16
Study: 12966478

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 20 to 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium <20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketorolac 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10839762

Group type: EXPERIMENTAL
Intervention: Azithromycin (3-month course)
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3300
Study: 8800985

Group type: EXPERIMENTAL
Intervention: Low dose dobutamine (5-10 micrograms/kg/min over 5 min)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: High dose dobutamine (20-40 micrograms/kg/min over 3 min)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Dipyridamole (0.56 mg/kg over 4 min + 0.28 mg/kg over 2 min)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Late spontaneous functional recovery
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sensitivity of dobutamine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sensitivity of dipyridamole
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Specificity of dobutamine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Specificity of dipyridamole
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Positive predictive value of dobutamine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Positive predictive value of dipyridamole
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Negative predictive value of dobutamine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Negative predictive value of dipyridamole
Number of subjects: 51
Study: 1516979

Group type: EXPERIMENTAL
Intervention: 25 mg clomiphene citrate daily for 6 months
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 6549194

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 micrograms every 6 hr during dietary intake of 22.3 mmoles Ca/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 micrograms every 6 hr during dietary intake of 9.3 mmoles Ca/day
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (before calcitriol administration) with dietary intake of 22.3 mmoles Ca/day
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (before calcitriol administration) with dietary intake of 9.3 mmoles Ca/day
Number of subjects: 6
Study: 31717571

Group type: EXPERIMENTAL
Intervention: Greater intake of less healthful food groups (sweet snacks, salty snacks, and sweetened beverages)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Greater intake of sweet snacks
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Greater intake of fruits
Number of subjects: 868
Study: 29783095

Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment initiated prior to release
Number of subjects: 199

Group type: COMPARATOR
Intervention: Buprenorphine treatment initiated after release
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 199
Study: 27430210

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (Riastap®) 60-70 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 40
Study: 25164471

Group type: EXPERIMENTAL
Intervention: Supervised physical therapy (3 sessions/week for 24 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Controlled home-based program (same duration as supervised)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study: 22249344

Group type: EXPERIMENTAL
Intervention: Tacrolimus QD
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tacrolimus BID
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 60
Study: 19843485

Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg, step-down dosing: 21 mg for 6 weeks, then 14 mg and 7 mg for 2-week periods)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 502
Study: 17451401

Group type: EXPERIMENTAL
Intervention: Nalmefene 10 to 40 mg
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study: 14693628

Group type: EXPERIMENTAL
Intervention: Classic posterior approach with 0.75% ropivacaine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Modified subgluteus posterior approach with 0.75% ropivacaine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Lateral popliteal approach with 0.75% ropivacaine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 75
Study: 11800375

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine-adrenaline solution (LA)
Number of subjects: 20
Study: 9689392

Group type: EXPERIMENTAL
Intervention: Children's and Infants Postoperative Pain Scale (CHIPPS)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Infants Postoperative Pain Scale (IPPS)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Piritramide
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 139

Group type: COMPARATOR
Intervention: CHIPPS vs IPPS
Number of subjects: 139
Study: 8133114

Group type: EXPERIMENTAL
Intervention: Primaquine (0.25 mg of base/kg of body weight/day over 14 days)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Chloroquine (25 mg of base/kg over 3 days)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Combined chloroquine-primaquine
Number of subjects: 85
Study: 2550245

Group type: EXPERIMENTAL
Intervention: Insulin 0.125 U.kg-1 + placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: hANP 100 micrograms + placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insulin + hANP
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 789791

Group type: EXPERIMENTAL
Intervention: Conventional A/England/42/72 (H3N2) vaccine (X‐37)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antigenic hybrid (Heq1N2) vaccine (X‐38)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 0
Study: 30302915

Group type: EXPERIMENTAL
Intervention: Autonomy-framed implementation intentions
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control-framed implementation intentions
Number of subjects: 300
Study: 27692565

Group type: EXPERIMENTAL
Intervention: Crofelemer
Number of subjects: 46

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 46
Study: 26165176

Group type: EXPERIMENTAL
Intervention: High plasma cis-lutein/zeaxanthin levels at 3 months
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High plasma α-tocopherol levels at 3 months
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High plasma β-cryptoxanthin levels at 3 months
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High plasma all-trans-lycopene levels at 3 months
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Percent increase in α-tocopherol levels from baseline to month 3
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Percent increase in trans-β-carotene levels from baseline to month 3
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Percent increase in β-cryptoxanthin levels from baseline to month 3
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Percent increase in cis-lutein/zeaxanthin levels from baseline to month 3
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Percent increase in all-trans-lycopene levels from baseline to month 3
Number of subjects: 39
Study: 23701469

Group type: EXPERIMENTAL
Intervention: Slow eccentric exercise (30° s(‐1))
Number of subjects: 17

Group type: COMPARATOR
Intervention: Fast eccentric exercise (210° s(‐1))
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both interventions (slow and fast eccentric exercise)
Number of subjects: 17
Study: 22167767

Group type: EXPERIMENTAL
Intervention: N(2)-L-alanyl-L-glutamine (GLN) 0.4 g/kg per day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 50
Study: 19484969

Group type: EXPERIMENTAL
Intervention: Euglycemic-hyperinsulinemic clamp after 2 week insulin intensive treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal control group (NC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2DM)
Number of subjects: 16
Study: 16377979

Group type: EXPERIMENTAL
Intervention: Ribose supplementation (10 g in 8 oz water)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Dextrose supplementation (10 g in 8 oz water)
Number of subjects: 31
Study: 12928639

Group type: EXPERIMENTAL
Intervention: Cariporide 120 mg
Number of subjects: 2998

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2998
Study: 10949007

Group type: EXPERIMENTAL
Intervention: CHO/PRO/FAT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 10

Group type: COMPARATOR
Intervention: PL
Number of subjects: 10
Study: 8846273

Group type: EXPERIMENTAL
Intervention: 4.5% Human albumin solution (HAS) (mean volume 25.6 ml.kg‐1, SD 9.5)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Haemaccel (Hoechst) (24.9 ml.kg‐1, SD 10)
Number of subjects: 30
Study: 1506807

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6380336

Group type: EXPERIMENTAL
Intervention: Nalbuphine 20 mg
Number of subjects: 52